Soleno jumps as Nuerocrine strikes $2.9 bln takeover deal

Neurocrine Biosciences

06/04/2026 12:35

Updates

** Shares of Soleno therapeutics SLNO.O rise 33.7% to $52.80 premarket

** Neurocrine Biosciences NBIX.O says it will buy Soleno in a deal worth $2.9 billion

** Neurocrine will pay $53 per share in cash for Soleno, a premium of 34.2% to Soleno's last close

** The deal is expected to close within 90 days, cos say

** Neurocrine shares were down 2.7% at $128 before the bell

** The deal gives Neurocrine access to Vykat XR, the first drug approved in the U.S. to treat hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder

** Up to last close, SLNO has fallen 14.7% this year

 (Reporting by Mrinalika Roy and Kamal Choudhury)